GSK - CureVac reports preclinical data on CV2COV vaccine in scientific journal

CureVac (NASDAQ:CVAC) announces the extended preclinical study of the second-generation vaccine candidate, CV2CoV, jointly developed with GlaxoSmithKline (NYSE:GSK), in the journal Nature. CVAC shares rise 5.2% premarket at $40.81. The newly published data features a direct comparison of CV2CoV with the licensed mRNA vaccine, Comirnaty(R) (Pfizer/BioNTech). Neutralizing antibody levels measured following full vaccination of animals with either 12µg of CV2CoV or a 30µg standard dose of Comirnaty were shown to be highly comparable. The data confirm how targeted optimizations of a non-chemically modified mRNA can significantly improve immune responses in a preclinical model, providing substantiated support for the unmodified mRNA technology approach. This applies not only to the development of COVID-19 vaccines but to the mRNA technology field as a whole.

For further details see:

CureVac reports preclinical data on CV2COV vaccine in scientific journal